Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MKYNT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DAR8-alphaCD30-mDPR-GlucQ-AE
|
|||||
| Synonyms |
DAR8 alphaCD30 mDPR glucQ AE
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Hodgkin lymphoma [ICD11:2B30]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD30 DAR8-alphaCD30-mDPR-glucQ-AE mAb
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Quaternary ammonium linker GlucQ
|
Linker Info | ||||
| Conjugate Type |
A self-stabilizing maleimide (mDPR) was utilized as the point of attachment for antibody conjugation.
|
|||||
| Combination Type |
GlucQ-AE
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.